Form 4: Vertex Pharmaceuticals Director Sangeeta N. Bhatia Reports Stock Transactions

Director Sangeeta N. Bhatia reported the acquisition and disposal of Vertex Pharmaceuticals (VRTX) common stock on August 30, 2024, according to a Form 4 filing with the SEC.

Summary

• On August 30, 2024, Sangeeta N. Bhatia, a director of Vertex Pharmaceuticals, executed transactions involving the company's common stock.
• Bhatia acquired 646 shares of common stock at a price of $152.74 per share through the exercise of stock options.
• Simultaneously, Bhatia disposed of 646 shares at a price of $500 per share.
• Following these transactions, Bhatia beneficially owns 4,435 shares of Vertex Pharmaceuticals common stock.
• The transactions were executed under a pre-arranged trading plan (Rule 10b5-1) established on May 9, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions by a company director under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's performance or future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.

Key Dates